Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 34 and last traded at GBX 34.55, with a volume of 121483 shares traded. The stock had previously closed at GBX 35.
Faron Pharmaceuticals Oy Stock Up 1.4%
The firm has a market capitalization of £72.02 million, a price-to-earnings ratio of -3.08 and a beta of 1.12. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 155.01. The firm has a 50 day moving average price of GBX 40.34 and a two-hundred day moving average price of GBX 43.64.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Recommended Stories
- Five stocks we like better than Faron Pharmaceuticals Oy
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
- Chewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for Investors
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
